LUND, Sweden--(BUSINESS WIRE)--
BioInvent International AB (BINV.ST)
BioInvent International AB (publ) (BINV.ST) today announced that the company’s total number of shares as per 30 August 2013 amounts to 85,014,649 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the rights issue of 10,560,826 shares with preferential right for the company’s shareholders that was announced on 19 June 2013 and the additional 528,041 shares that were issued in a so-called over-allotment option in connection to the rights issue.
To the editors:
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.
The Company's competitive position is underpinned by n-CoDeR®, a proprietary antibody development platform. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.
Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.45 a.m. CET, on 30 August 2013.
- Investment & Company Information
President and CEO
+46 (0)46 286 85 67
+46 (0)707 18 89 30
BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Phone: +46 (0)46 286 85 50